Trial Profile
A Multicentric Clinical-Practice Based Cohort Study Evaluating Effectiveness And Identifying Predictors Of Response To Belimumab In Patients With Active Systemic lupus erythematosus (SLE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jun 2019
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 15 Jun 2019 Results assessing effectiveness and safety of belimumab,presented at the 20th Annual Congress of the European League Against Rheumatism.
- 24 Oct 2018 Results assessing safety and efficacy of response to belimumab in patients with active Systemic Lupus Erythematosus, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 17 Jun 2017 Results (n=48) assessing the effect of belimumab treatment on skin involvement, presented at the 18th Annual Congress of the European League Against Rheumatism